Journal of the International AIDS Society

Table 2 Selected Investigational Antiretroviral Drugs in Phase 2-3 Studies

From: Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future

Class	Agent	Manufacturer
NRTI	Alovudine (MIV-310)	Medivir
	Amdoxovir (DAPD)	RFS Pharmaceuticals
	AVX754	Avexa
	Elvucitabine (ACH-126)	Achillion
	Racivir (PSI 5004)	Pharmasset
	Reverset (D-D4FC)	Pharmasset
NNRTI	695634	GlaxoSmithKline
	Calanolide A	Sarawak MediChem
	DPC 083	Bristol-Myers Squibb
	Etravirine (TMC 125)	Tibotec
	MIV-150	Medivir
	TMC-278	Tibotec
PI	DPC-681	Bristol-Myers Squibb
	GW640385	GlaxoSmithKline
	L-756423	Merck
	RO033-4649	Roche
	TMC-114	Tibotec
Fusion/Entry Inhibitor	AMD070	Anormed
	Aplaviroc*	GlaxoSmithKline
	BMS-488043	Bristol-Myers Squibb
	FP-21399	EMD Lexigen
	Maraviroc (UK 427)	Pfizer
	PRO 140	Progenics
	PRO 542	Progenics
	TNX-355	Tanox
	Vicriviroc (SCH 417)	Schering

NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = nonnucleoside reverse transcriptase inhibitor; PI = protease inhibitor. Adapted from "2005 Antiretrovirals Pipeline," available at: http://www.aidsinfonyc.org (accessed December 8, 2005) and from the University of California at San Francisco Center for HIV Information, "FDA-Approved and Investigational Antiretrovirals," available at: http://hivinsite.ucsf.edu/ (accessed December 6, 2005).
* Development halted October 2005.

Back to article page